<DOC>
	<DOCNO>NCT00146237</DOCNO>
	<brief_summary>About two-thirds depressed patient respond standard course serotonin specific reuptake inhibitor ( SSRI 's ) within 3-4 week . While clinician advise continue watchful wait time switch different reuptake-blocker base antidepressant , result conservative strategy usually disappoint . For severe depression electroconvulsive therapy ( ECT ) option atypical depression monoamine oxide inhibitor ( MAO ) inhibitor often give relief point . A unique strategy theoretical practical implication lithium augmentation ( Fava et al , 1994 ) . Addition lithium SSRI failures 3-4 week consistently sometimes dramatically find helpful . This consider true even author advocate use lithium usual circumstance bipolar patient . Lithium recent year join mood stabilizer carbamazepine valproate . Phenytoin , ignore many year possible anticonvulsant mood stabilizer , recently report double-blind control trial anti-manic ( Mishory et al , 2000 ) also prophylactic BP disorder ( Mishory et al , 2003 ) . Data mood stabilizer lithium augmentors SSRI failure sparse . Carbamazepine ( Steinacher et al , 2002 ) valproate ( Barbee et al , 2002 ) use . Given recent preliminary result phenytoin 's efficacy unipolar depression ( Nemets et al , 2005 ) analogy lithium mood stabilizer , seem important study phenytoin possible augmentation SSRI failure . We publish negative study previously inositol augmentation SSRI failure , enrol forty-two patient two year ( Nemets et al , 1999 ) . Antidepressant failure easy recruit refer physician center untreated patient , clinician reluctant refer new drug study give adequacy standard treatment 2/3 . Thus estimate could enroll 20 patient per year study . Survey literature Li augmentation suggest 40 phenytoin vs. 40 placebo give adequate power detect significant phenytoin effect phenytoin effect similar lithium .</brief_summary>
	<brief_title>Phenytoin Augmentation SSRI Failures</brief_title>
	<detailed_description>About two-thirds depressed patient respond standard course serotonin specific reuptake inhibitor ( SSRI 's ) within 3-4 week . While clinician advise continue watchful wait time switch different reuptake-blocker base antidepressant , result conservative strategy usually disappoint . For severe depression electroconvulsive therapy ( ECT ) option atypical depression monoamine oxide inhibitor ( MAO ) inhibitor often give relief point . A unique strategy theoretical practical implication lithium augmentation ( Fava et al , 1994 ) . Addition lithium SSRI failures 3-4 week consistently sometimes dramatically find helpful . This consider true even author advocate use lithium usual circumstance bipolar patient . Lithium recent year join mood stabilizer carbamazepine valproate . Phenytoin , ignore many year possible anticonvulsant mood stabilizer , recently report double-blind control trial anti-manic ( Mishory et al , 2000 ) also prophylactic BP disorder ( Mishory et al , 2003 ) . Data mood stabilizer lithium augmentors SSRI failure sparse . Carbamazepine ( Steinacher et al , 2002 ) valproate ( Barbee et al , 2002 ) use . Given recent preliminary result phenytoin 's efficacy unipolar depression ( Nemets et al , 2005 ) analogy lithium mood stabilizer , seem important study phenytoin possible augmentation SSRI failure . We publish negative study previously inositol augmentation SSRI failure , enrol forty-two patient two year ( Nemets et al , 1999 ) . Antidepressant failure easy recruit refer physician center untreated patient , clinician reluctant refer new drug study give adequacy standard treatment 2/3 . Thus estimate could enroll 20 patient per year study . Survey literature Li augmentation suggest 40 phenytoin vs. 40 placebo give adequate power detect significant phenytoin effect phenytoin effect similar lithium . The study approve Helsinki Committee patient must give write informed consent . Patients evaluate study meet DSM-IV criterion major depression without psychotic feature . Patients enter study least 3 week treatment SSRI clinically adequate dos ( 150mg fluvoxamine , 20mg fluoxetine , 20mg paroxetine ) still score least 18 Hamilton Depression Scale ( HDS ) ( 24 item scale ) mild improvement onset SSRI treatment . Patients alcohol drug abuse patient unstable medical illness exclude . Design parallel double-blind . Patients continue SSRI treatment medication dose receive entry . They randomly assign phenytoin identical placebo capsule . Patients rat HDRS weekly four week addition phenytoin placebo . Patients improve least 1 unit GCI every two week drop study ethical reason refer open treatment . HDRS rating do weekly experience psychiatrist ( BN ) blind treatment medication . Blood level phenytoin report lab treat psychiatrist `` dummy '' level assign control psychiatrist patient placebo . All patient evaluate physically EKG , liver kidney function , blood cell count perform enter study . Special attention give instruction patient dental hygiene patient show sign gingival hyperplasia drop . Studies epilepsy show side effect surprisingly uncommon , despite wide publicity . No case see previous short-term study prophylactic study ( Mishory et al , 2000 ; Mishory et al , 2003 ) . Nonlinear pharmacokinetics , drug interaction consequent danger toxicity handle careful blood level monitoring . Patients significant side effect toxicity drop study . Patients indication hypersensitivity reaction ( morbilliform rash , Stevens-Johnson syndrome , systemic lupus erythematosus , hepatic necrosis , neutropenia leukopenia , red-cell aplasia , agranulocytosis , aplastic- megalo- anemia , thrombocytopenia ) drop study . Importance : Almost one third patient fail respond standard antidepressant . Proof efficacy phenytoin augmentation case would : 1 ) useful addition clinical armamentarium 2 ) strengthen theoretical profile phenytoin antimanic , antidepressant mood stabilize compound parallel lithium several anticonvulsant 3 ) raise useful heuristic idea mechanistic study phenytoin 's effect mood . References Barbee JG , Jamhour NJ . ( 2002 ) . Lamotrigine augmentation agent treatment-resistant depression . J Clin Psychiatry 63:737-741 . Fava M , Rosenbaum J , McGrath P , et al . ( 1994 ) . Lithium tricyclic augmentation fluoxetine treatment resistant major depression . Am J Psychiatry 15:1372-1374 . Mishory A , Yaroslavsky Y , Bersudsky Y , Belmaker RH . ( 2000 ) . Phenytoin antimanic anticonvulsant : control study . American Journal Psychiatry 157:463-465 . Mishory A , Winokur M , Bersudsky Y. ( 2003 ) . Prophylactic effect phenytoin BP disorder : control study . Bipolar Disorder 5 ( 6 ) :464-7 . Nemets B , Stahal Z , Belmaker RH ( 2002 ) . Omega-3 fatty acid treatment depressive breakthrough unipolar maintenance . American Journal Psychiatry 159:477-479 . Nemets B , Mishory A , Levine J , Belmaker RH . ( 1999 ) . Inositol addition improve depression SSRI treatment failure . Journal Neural Transmission 106:795-798 . Nemets B &amp; Levine J ( 2005 ) . Phenytoin equivalent fluoxetine unipolar depression : control study 66 ( 5 ) :586-90 . Steinacher L , Vandel P , Zullino DF , CB Eap , Brawand-Amey M , Baumann P. ( 2002 ) . Carbamazepine augmentation depressive patient non-responding citalopram : pharmacokinetic clinical pilot study . Eur Neuropsychopharmacol 12:255-260 .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Phenytoin</mesh_term>
	<criteria>age : 1865 DSMIV criterion major depression without psychotic feature least 3 week treatment SSRI clinically adequate dose mild improvement onset SSRI treatment Hamilton Depression Scale score least 18 ideation suicide pregnancy drug alcohol abuse unstable medical illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>phenytoin</keyword>
	<keyword>SSRI failure</keyword>
	<keyword>depression</keyword>
</DOC>